CannBioRx Life Sciences Corp (ATNFW) - Total Assets
Based on the latest financial reports, CannBioRx Life Sciences Corp (ATNFW) holds total assets worth $10.71 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CannBioRx Life Sciences Corp - Total Assets Trend (2016–2024)
This chart illustrates how CannBioRx Life Sciences Corp's total assets have evolved over time, based on quarterly financial data. Also see ATNFW stock market capitalisation for the company's overall valuation and market capitalisation.
CannBioRx Life Sciences Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
CannBioRx Life Sciences Corp's total assets of $10.71 Million consist of 40.3% current assets and 59.7% non-current assets. Review CannBioRx Life Sciences Corp debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.9% |
| Accounts Receivable | $41.19K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.62 Million | 59.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how CannBioRx Life Sciences Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CannBioRx Life Sciences Corp share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CannBioRx Life Sciences Corp's current assets represent 40.3% of total assets in 2024, an increase from 28.0% in 2016.
- Cash Position: Cash and equivalents constituted 35.9% of total assets in 2024, up from 0.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 59.7% of total assets.
CannBioRx Life Sciences Corp Competitors by Total Assets
Key competitors of CannBioRx Life Sciences Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
CannBioRx Life Sciences Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 0.58 | 0.18 |
| Quick Ratio | 0.58 | 0.58 | 0.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.24 Million | $-1.67 Million | $-3.28 Billion |
CannBioRx Life Sciences Corp - Advanced Valuation Insights
This section examines the relationship between CannBioRx Life Sciences Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 142.7% |
| Total Assets | $12.76 Million |
| Market Capitalization | $4.09K USD |
Valuation Analysis
Below Book Valuation: The market values CannBioRx Life Sciences Corp's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CannBioRx Life Sciences Corp's assets grew by 142.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CannBioRx Life Sciences Corp (2016–2024)
The table below shows the annual total assets of CannBioRx Life Sciences Corp from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $12.76 Million | +142.67% |
| 2023-12-31 | $5.26 Million | -73.23% |
| 2022-12-31 | $19.65 Million | -68.67% |
| 2021-12-31 | $62.71 Million | +12.93% |
| 2020-12-31 | $55.53 Million | +7.03% |
| 2019-12-31 | $51.88 Million | -56.19% |
| 2018-12-31 | $118.44 Million | +1.18% |
| 2017-12-31 | $117.06 Million | +48674.31% |
| 2016-12-31 | $240.00K | -- |
About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more